Payload Information
General Information of This Payload
| Payload ID | PAY0ZPNIM |
|||||
|---|---|---|---|---|---|---|
| Name | P4 payload |
|||||
| Synonyms |
P4 payload
Click to Show/Hide
|
|||||
| Structure |
|
|||||
| Formula | C54H57N7O6 |
|||||
| Isosmiles | CN1C(C2=CC3=C(C=C2C(N4CC(C=CC=C5)=C5C[C@H]4C)=O)CN(C(CC6=CC=C(OCCN7CCOCC7)C=C6)=O)CC3)=CC(C(N(C(C=C8C#N)=C(N8C)C)C9=CC=C(O)C=C9)=O)=C1C |
|||||
| InChI |
InChI=1S/C54H57N7O6/c1-35-26-39-8-6-7-9-41(39)34-60(35)53(64)49-29-42-33-59(52(63)27-38-10-16-46(17-11-38)67-25-22-58-20-23-66-24-21-58)19-18-40(42)28-48(49)51-31-47(36(2)57(51)5)54(65)61(43-12-14-45(62)15-13-43)50-30-44(32-55)56(4)37(50)3/h6-17,28-31,35,62H,18-27,33-34H2,1-5H3/t35-/m1/s1
|
|||||
| InChIKey |
SITZKQHHKBJYST-PGUFJCEWSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
900.093 |
Polar area |
136.51 |
||
Complexity |
2824.440137 |
xlogp Value |
7.62862 |
|||
Heavy Count |
67 |
Rot Bonds |
11 |
|||
Hbond acc |
10 |
Hbond Donor |
1 |
|||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
NY920-P1-L12-P4 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.011 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L12-P4 was tested in KMS-27
|
||||
| In Vitro Model | Plasma cell myeloma, Multiple myeloma | KMS-27 cells | CVCL_2993 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.027 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L12-P4 was tested in Ke97
|
||||
| In Vitro Model | Bladder carcinoma | Ke97 cells | CVCL_3386 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.036 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L12-P4 was tested in KHM-1B
|
||||
| In Vitro Model | Plasma cell myeloma, Multiple myeloma | KHM-1B cells | CVCL_2972 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.07 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L12-P4 was tested in NCI-H929
|
||||
| In Vitro Model | Plasma cell myeloma | NCI-H929 cells | CVCL_1600 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.254 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L12-P4 was tested in KMS-21-BM
|
||||
| In Vitro Model | Multiple myeloma | KMS-21-BM cells | CVCL_2991 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.531 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L12-P4 was tested in AMO-1
|
||||
| In Vitro Model | Multiple myeloma, Plasma cell myeloma | AMO-1 cells | CVCL_1806 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 10 nM | High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L12-P4 was tested in MOLP-8
|
||||
| In Vitro Model | Plasma cell myeloma | MOLP-8 cells | CVCL_2124 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
19.67 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L12-P4 was tested in RL
|
||||
| In Vitro Model | Diffuse large B-cell lymphoma | RL cells | CVCL_1660 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | < 50 nM | High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L12-P4 was tested in WSU-DLCL2
|
||||
| In Vitro Model | Diffuse large B-cell lymphoma | WSU-DLCL2 cells | CVCL_1902 | ||
CD74 Milatuzumab DANAPAE152C S375C-P1-L12-P4 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.03 nM
|
High CD74 expression (CD74 +++) | ||
| Method Description |
CD74 Milatuzumab DANAPAE152C S375C-P1-L12-P4 was tested in EOL-1
|
||||
| In Vitro Model | Chronic eosinophilic leukemia | EoL-1 cells | CVCL_0258 | ||
NY920-P1-L17-P4 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.031 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L17-P4 was tested in KNM-1B
|
||||
| In Vitro Model | Plasma cell myeloma, Multiple myeloma | KHM-1B cells | CVCL_2972 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.041 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L17-P4 was tested in KMS-27
|
||||
| In Vitro Model | Plasma cell myeloma, Multiple myeloma | KMS-27 cells | CVCL_2993 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.133 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L17-P4 was tested in NCI-H929
|
||||
| In Vitro Model | Plasma cell myeloma | NCI-H929 cells | CVCL_1600 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.33 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L17-P4 was tested in KMS-21-BM
|
||||
| In Vitro Model | Multiple myeloma | KMS-21-BM cells | CVCL_2991 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
1.11 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L17-P4 was tested in Ke97
|
||||
| In Vitro Model | Bladder carcinoma | Ke97 cells | CVCL_3386 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
1.48 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L17-P4 was tested in WSU-DLCL2
|
||||
| In Vitro Model | Diffuse large B-cell lymphoma | WSU-DLCL2 cells | CVCL_1902 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
1.49 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L17-P4 was tested in AMO-1
|
||||
| In Vitro Model | Multiple myeloma, Plasma cell myeloma | AMO-1 cells | CVCL_1806 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 5 nM | High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L17-P4 was tested in MOLP-8
|
||||
| In Vitro Model | Plasma cell myeloma | MOLP-8 cells | CVCL_2124 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
23.6 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L17-P4 was tested in RL
|
||||
| In Vitro Model | Diffuse large B-cell lymphoma | RL cells | CVCL_1660 | ||
IgG-P1-L12-P4 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
3.05 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
lgG-P1-L12-P4 was tested in KMS-27
|
||||
| In Vitro Model | Plasma cell myeloma, Multiple myeloma | KMS-27 cells | CVCL_2993 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
20.47 nM
|
High CD48 expression (CD48 +++) | ||
| Method Description |
lgG-P1-L12-P4 was tested in RL
|
||||
| In Vitro Model | Diffuse large B-cell lymphoma | RL cells | CVCL_1660 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 50 nM | High CD48 expression (CD48 +++) | ||
| Method Description |
lgG-P1-L12-P4 was tested in KHM-1B
|
||||
| In Vitro Model | Plasma cell myeloma, Multiple myeloma | KHM-1B cells | CVCL_2972 | ||